Accera, Inc. to Present at UBS Global Life Sciences Conference
Posted on: Friday, 18 September 2009, 12:58 CDT
BROOMFIELD, Colo., Sept. 18 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced today that it will present at the UBS Global Life Sciences Conference September 21-23, 2009 in New York.
Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona(TM) on Monday, September 21 at 11:30 a.m. EDT.
About Axona(TM)
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.
About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US. Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients. Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. Accera engages in research, development and commercialization of other clinical applications for Axona, and has a wholly owned subsidiary, Neuera Pharmaceuticals, with a pipeline of small molecule drugs for neurodegenerative diseases.
For more information about Accera, please visit www.accerapharma.com.
Contacts: Accera, Inc. Steve Orndorff, Ph.D. President and CEO sorndorff@accerapharma.com Tiberend Strategic Advisors, Inc. (212) 827-0020 Andrew Mielach amielach@tiberendstrategicadvisors.comSOURCE Accera, Inc.
Source: PR Newswire
Related Articles
- How To Better Recruit Volunteers For Alzheimer's Clinical Studies
- Hard To Treat Diseases (HTDS) Clinical Trials of Nutriprotein
- Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
- Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development
- Controversy About Lack of Placebo Group Decline in Alzheimer's Clinical Trials
- Home Visits Improve Willingness to Participate in Alzheimer's Clinical Trials
- Amarin Reports Preliminary Results From Parkinson's Disease Pre-Clinical Program Using Miraxion
- Alzheimer's Clinic Set to Open at U. In January
- Dr. Gott: Rare Wilson's Disease Involves Copper Metabolism
- Symbollon Initiates Phase III Fibrocystic Breast Disease Pivotal Clinical Trial for IoGen; Company To Build Upon Successful Phase II Study As Patient Enrollment Begins in January
 |
 |
User Comments (0)
RSS Feeds